87 results
8-K
EX-99.1
INVA
Innoviva Inc
29 Feb 24
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
4:15pm
million as of December 31, 2023.
Key 2023 R&D Highlights
Zoliflodacin: potential first-in-class oral antibiotic to treat uncomplicated gonorrhea
8-K
EX-99.1
INVA
Innoviva Inc
24 May 23
Corporate Presentation May 2023
5:18pm
dislocation, providing long - term upside Innovative anti - infectives R&D Armata has R&D and manufacturing capabilities along with a platform … for psychiatric and neurological disorders Nanolive is a microscopy company that has developed a method for live cell 3D imaging and analysis with applications across drug discovery and biotech R&D Strategic Healthcare Assets
8-K
EX-99.1
INVA
Innoviva Inc
9 Nov 22
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:17pm
not already owned by Innoviva for $42.4 million. Entasis brings to Innoviva an infectious disease focused R&D platform anchored by its lead asset sulbactam
8-K
EX-99.1
INVA
Innoviva Inc
14 Sep 22
Regulation FD Disclosure
5:22pm
healthcare expertise across governance, strategy, medicine / science, R&D, finance, and operations 2 High-potential, robust operating platform … to healthcare Entasis / La Jolla combination creates an integrated therapeutics platform with strong R&D engine and superior hospital-focused
8-K
EX-10.1
80ccku
13 Jul 22
Entry into a Material Definitive Agreement
5:27pm
SC TO-C
EX-99.2
we7b6xg hi
23 May 22
Information about tender offer
8:54pm
SC TO-C
EX-99.3
zoh3rhu7tt 8aot
23 May 22
Information about tender offer
8:53pm
8-K
EX-99.3
wwpxtdavkcj9pa noue
23 May 22
Tender and Support Agreement
8:51pm
8-K
EX-99.1
f4oibb
7 Apr 22
Regulation FD Disclosure
5:09pm
8-K
EX-99.1
3uoixy ekocv75k3
13 Dec 21
Corporate Presentation December 2021
4:39pm